Could a seizure drug lift bipolar depression?

NCT ID NCT07412132

Recruiting now Symptom relief Sponsor: University of Sao Paulo Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This phase 3 trial tests whether adding lacosamide to standard treatment helps people with bipolar disorder who are currently in a major depressive episode. Forty adults who haven't responded to at least two prior treatments will receive either lacosamide or a placebo for 12 weeks. The study measures changes in depression scores using a standard rating scale.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: lacosamide
What this could lead to: If it works, this could point toward a new add-on treatment for depression in bipolar disorder that is hard to treat.
What could go wrong: This is a small pilot study with only 40 people, so results may not apply widely. Lacosamide also carries risks like dizziness and nausea.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BIPOLAR AFFECTIVE DISORDER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

bipolar disorder bipolar I disorder bipolar II disorder major affective disorder 6

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BIPOLAR AFFECTIVE DISORDER

Contacts and locations

Locations

Instituto de Psiquiatia (IPQ)
RECRUITING

São Paulo, São Paulo, Brazil

More trials for these conditions

Other studies related to the condition(s) this trial covers.